Literature DB >> 6361850

Nitroimidazoles as chemotherapeutic agents.

M D Nair, K Nagarajan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6361850     DOI: 10.1007/978-3-0348-7115-0_4

Source DB:  PubMed          Journal:  Prog Drug Res        ISSN: 0071-786X


× No keyword cloud information.
  5 in total

1.  Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess.

Authors:  Jameel Muzaffar; Kaushal Madan; M P Sharma; Premashish Kar
Journal:  Dig Dis Sci       Date:  2006-11-11       Impact factor: 3.487

2.  Anti-Helicobacter pylori activity and Structure-Activity Relationship study of 2-Alkylthio-5-(nitroaryl)-1,3,4-thiadiazole Derivatives.

Authors:  Ali Asadipour; Najmeh Edraki; Maryam Nakhjiri; Azadeh Yahya-Meymandi; Eskandar Alipour; Parastoo Saniee; Farideh Siavoshi; Abbas Shafiee; Alireza Foroumadi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

3.  Nitroimidazooxazoles(#) Part xxiv, Search for Antileishmanial Agents: 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles as Potential Antileishmanial Agents.

Authors:  S P Nayak; K Sundarraja Rao; K Nagarajan; K Shridhara; E Torreele; B B Trunz
Journal:  Indian J Pharm Sci       Date:  2014-01       Impact factor: 0.975

4.  Clinical and microbiological efficacy of 3% satranidazole gel as a local drug delivery system in the treatment of chronic periodontitis: A randomized, controlled clinical trial.

Authors:  N Priyanka; Nitish Kalra; Shahab Saquib; Nitin Kudyar; Nikhil Malgaonkar; Hunny Jain; A R Pradeep
Journal:  Contemp Clin Dent       Date:  2015 Jul-Sep

5.  Synthesis and biological evaluation of novel benzyl piperazine derivatives of 5-(5-nitroaryl)-1,3,4-thiadiazoles as Anti-Helicobacter pylori agents.

Authors:  Negar Mohammadhosseini; Parastoo Saniee; Ameneh Ghamaripour; Hassan Aryapour; Farzaneh Afshar; Najmeh Edraki; Farideh Siavoshi; Alireza Foroumadi; Abbas Shafiee
Journal:  Daru       Date:  2013-08-08       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.